Compare CMCT & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCT | GOVX |
|---|---|---|
| Founded | 1993 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.7M |
| IPO Year | 1996 | N/A |
| Metric | CMCT | GOVX |
|---|---|---|
| Price | $2.36 | $1.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $200.00 |
| AVG Volume (30 Days) | 47.0K | ★ 126.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $124,512,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $0.21 | $0.12 |
| 52 Week High | $14.41 | $4.40 |
| Indicator | CMCT | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 40.02 |
| Support Level | N/A | $0.55 |
| Resistance Level | $7.67 | $4.40 |
| Average True Range (ATR) | 0.17 | 0.24 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 40.09 | 20.70 |
Creative Media & Community Trust Corp is formed to invest in, own, and operate Class A and creative office investments in improving urban communities throughout the United States. It operates through segments such as office, hotel and multifamily properties and lending. The Office segment includes rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment relates to operations of hotel properties whereas, the lending segment refers to income from the yield and other related fee income earned on its loans receivable. The lending segment includes income recognized from the sale of government guaranteed portion of loans receivable, income from the yield on its loans receivable and other related fee income earned.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.